{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:33:53Z","timestamp":1790735633018,"version":"4.1.0"},"reference-count":29,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: In early-stage HER2-positive breast cancer, ado-trastuzumab emtansine (T-DM1) has been adopted as the preferred adjuvant approach for patients left with residual invasive disease despite neoadjuvant therapy. The influence of different neoadjuvant regimens on subsequent outcomes in real-world settings remains uncertain. Materials and Methods: From 2019 to 2025, 102 patients treated with adjuvant T-DM1 following surgery after neoadjuvant chemotherapy were retrospectively assessed. Neoadjuvant regimens included doxorubicin plus cyclophosphamide followed by trastuzumab-paclitaxel, doxorubicin plus cyclophosphamide with pertuzumab\u2013trastuzumab\u2013docetaxel, or docetaxel\u2013carboplatin\u2013trastuzumab\u2013pertuzumab. Clinical features, treatment response, survival, and toxicity were evaluated. Results: The mean age of the cohort was 49.7 years, and the majority of patients (80.4%) were aged 40 years or older. Hormone receptor positivity was 82.0%, and invasive ductal carcinoma accounted for 97.1% of cases. Regional responses included 39.2% with axillary pCR despite residual breast lesions, and 5.9% with breast pCR accompanied by axillary disease. Kaplan\u2013Meier analysis demonstrated disease-free survival rates of 100%, 95.2%, and 92.2% at 1, 3, and 5 years, respectively. Adverse events were predominantly grade 1\u20132, while grade 3\u20134 toxicities occurred in under 5% of the cohort. Baseline characteristics varied across regimens, reflecting real-world treatment preferences, but survival outcomes remained comparable. Conclusions: Adjuvant T-DM1 was associated with high survival rates and manageable toxicity across different neoadjuvant regimens, underscoring its consistent benefit in routine clinical practice.<\/jats:p>","DOI":"10.3390\/medicina61111966","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:55:22Z","timestamp":1762178122000},"page":"1966","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neoadjuvant Regimens and Their Impact on Adjuvant T-DM1 Outcomes in HER2-Positive Early Breast Cancer"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5528-7852","authenticated-orcid":false,"given":"Ahmet Burak","family":"Agaoglu","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4859-7574","authenticated-orcid":false,"given":"Atike Pinar","family":"Erdogan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9317-942X","authenticated-orcid":false,"given":"Ferhat","family":"Ekinci","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Sahbazlar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Manisa Celal Bayar University, Manisa 45030, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guler Nur","family":"Tekustun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Mugla Sitki Kocman University, Mugla 48000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0598-7284","authenticated-orcid":false,"given":"Ozgur","family":"Tanriverdi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Mugla Sitki Kocman University, Mugla 48000, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salih","family":"Tunbekici","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Ege University, Izmir 35100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6180-713X","authenticated-orcid":false,"given":"Erdem","family":"Goker","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Ege University, Izmir 35100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Sinan","family":"Akarca","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Dokuz Eylul University, Izmir 35340, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1400-0594","authenticated-orcid":false,"given":"Can","family":"Cangur","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Selcuk University, Konya 42075, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taliha","family":"Guclu Kantar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Pamukkale University, Denizli 20070, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1053-0668","authenticated-orcid":false,"given":"Sedat","family":"Biter","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8713-7613","authenticated-orcid":false,"given":"Ertugrul","family":"Bayram","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana 01330, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3802-461X","authenticated-orcid":false,"given":"Gokhan","family":"Colak","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Aydin Adnan Menderes University, Aydin 09100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4380-9419","authenticated-orcid":false,"given":"Bilgin","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Aydin Adnan Menderes University, Aydin 09100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Basir","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Mersin University, Mersin 33110, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vehbi","family":"Ercolak","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Mersin University, Mersin 33110, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2021). Trastuzumab for Early-Stage HER2-Positive Breast Cancer: Meta-Analysis of Individual Patient Data from 13,864 Women in Seven Randomised Trials. Lancet Oncol., 22, 1139\u20131150."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer","volume":"353","author":"Procter","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1016\/S0140-6736(19)30650-6","article-title":"6 versus 12 Months of Adjuvant Trastuzumab for HER2-Positive Early Breast Cancer (PERSEPHONE): 4-Year Disease-Free Survival Results of a Randomised Phase 3 Non-Inferiority Trial","volume":"393","author":"Earl","year":"2019","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.annonc.2022.06.009","article-title":"VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years\u2019 follow-up","volume":"33","author":"Loibl","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and Safety of Neoadjuvant Pertuzumab and Trastuzumab in Women with Locally Advanced, Inflammatory, or Early HER2-Positive Breast Cancer (NeoSphere): A Randomised Multicentre, Open-Label, Phase 2 Trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer","volume":"380","author":"Huang","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2021.04.011","article-title":"Adjuvant T-DM1 versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses from KATHERINE","volume":"32","author":"Mamounas","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1200\/JCO.23.02170","article-title":"Adjuvant Trastuzumab Emtansine versus Paclitaxel plus Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): 10-Year Outcomes from a Randomised Phase 2 Trial","volume":"42","author":"Tarantino","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Krasniqi, E., Fabi, A., Caputo, R., Barchiesi, G., Giannarelli, D., Ciccarese, M., Pizzuti, L., Michelotti, A., Santini, D., and Giotta, F. (2024). Tolerability and Preliminary Outcomes of Adjuvant Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer after Neoadjuvant Therapy: The ATD Study. Cancers, 16.","DOI":"10.3390\/cancers16234104"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Wang, F., Zhang, Y., Liu, L., Huang, Y., Li, Q., Zhao, H., Chen, S., Xu, B., Yang, J., and Zhou, Y. (2025). Clinical Characteristics and Survival of Thrombocytopenia Induced by Trastuzumab Emtansine (T-DM1) in Patients with HER2-Positive Breast Cancer: A Real-World Study from China. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1592440"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomised phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1158\/1078-0432.CCR-22-1989","article-title":"Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer","volume":"29","author":"Denkert","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant Trastuzumab in HER2-Positive Breast Cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant Chemotherapy with or without Anthracyclines in the Presence of Dual HER2 Blockade for HER2-Positive Breast Cancer (TRAIN-2): A Multicentre, Open-Label, Randomised, Phase 3 Trial","volume":"19","author":"Mandjes","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/annonc\/mdx494","article-title":"De-escalation strategies in HER2-positive early breast cancer (EBC): Final analysis of the WSG-ADAPT HER2+\/HR\u2013 Phase II Trial: Efficacy, safety, and predictive markers for 12\u2009weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab \u00b1 weekly paclitaxel","volume":"28","author":"Nitz","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1002\/cncr.32392","article-title":"Trastuzumab Emtansine with or without Pertuzumab versus Trastuzumab + Taxane for HER2-Positive Advanced Breast Cancer: Final Results from the MARIANNE Trial","volume":"125","author":"Perez","year":"2019","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab Emtansine versus Treatment of Physician\u2019s Choice for Pretreated HER2-Positive Advanced Breast Cancer (TH3RESA): A Randomised, Open-Label, Phase III Trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3892\/ol.2023.14110","article-title":"Early Thrombocytopenia Predicts Longer Time-to-Treatment Discontinuation in Trastuzumab Emtansine Treatment","volume":"26","author":"Caner","year":"2023","journal-title":"Oncol. Lett."},{"key":"ref_21","first-page":"100772","article-title":"Real world Data on the Demographic and Clinicopathological Profile and Management of Patients with Early-Stage HER2-Positive Breast Cancer and Residual Disease Treated with Adjuvant Trastuzumab Emtansine (KARMA Study)","volume":"37","author":"Garate","year":"2023","journal-title":"Cancer Treat. Res. Commun."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Gupta, A., Sansar, B., Mishra, B.K., Khan, A., Singh, A., Upadhyay, A., Chowdhury, Z., Patne, S., Tripathi, M., and Shukla, S. (2025). Real-World Data on Trastuzumab Emtansine (TDM1) Efficacy and Safety: Results of a Single-Centre Retrospective Study of HER2-Positive Metastatic Breast Cancer Patients. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-97923-2"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/CAD.0000000000001717","article-title":"Real-Life Data on Adjuvant Trastuzumab Emtansine Treatment in Early-Stage HER2-Positive Breast Cancer: A Turkish Oncology Group Study","volume":"36","author":"Seven","year":"2025","journal-title":"Anti-Cancer Drugs"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Prat, A., Guarneri, V., Pascual, T., Bras\u00f3-Maristany, F., Sanfeliu, E., Par\u00e9, L., Schettini, F., Mart\u00ednez, D., Jares, P., and Griguolo, G. (2022). Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. eBioMedicine, 75.","DOI":"10.1016\/j.ebiom.2021.103801"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","article-title":"Customizing Therapies for Women with Early Breast Cancer: St. Gallen International Consensus Guidelines 2021","volume":"32","author":"Burstein","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1001\/jamaoncol.2024.3679","article-title":"Heterogeneity of Residual Disease after Neoadjuvant Systemic Therapy in Breast Cancer: A Review","volume":"10","author":"Tarantino","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/annonc\/mdz007","article-title":"Association of Tumor-Infiltrating Lymphocytes with Distant Disease-Free Survival in the ShortHER Randomized Adjuvant Trial for Patients with Early HER2+ Breast Cancer","volume":"30","author":"Dieci","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, Trastuzumab, and Docetaxel for HER2-Positive Metastatic Breast Cancer (CLEOPATRA): End-of-Study Results from a Double-Blind, Randomised, Placebo-Controlled, Phase 3 Study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N. Engl. J. Med."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/1966\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:45:47Z","timestamp":1762181147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/1966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["medicina61111966"],"URL":"https:\/\/doi.org\/10.3390\/medicina61111966","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}